ABBV vs MRK
AbbVie and Merck & Co., both Healthcare
AbbVie is the larger company at $382B against $281B. On trailing earnings ABBV is the cheaper of the two at a P/E of 78.1 against 115.5, a gap that is only a bargain if the two are growing at similar rates. Over the past year MRK returned +83% against +27% for ABBV. The RyuScore puts MRK ahead, 78 against 52 out of 100.
| Figure | ABBV | MRK |
|---|---|---|
| Last close | $276 | $146 |
| Market cap | $382B | $281B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 78.1 | 115.5 |
| Dividend yield | 2.4% | 2.3% |
| 1-year return | +27% | +83% |
| 5-year return | +207% | +132% |
| RyuScoresector-relative, 1–10 | 52/100 | 78/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AbbVie
Revenue of $17B in Q2 2026, net income $3.6B. Its largest reported line is SKYRIZI, 36% of the disclosed total.
Merck & Co.
Revenue of $17B in Q2 2026, net income null. Its largest reported line is Keytruda, 49% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.